Collaboration Is the Key to Success in CME: Takeaways From MAACME 2019

i3 Health staff attended the 9th annual conference of the Mid-Atlantic Alliance for Continuing Medical Education (MAACME) last week in Harrisburg, PA. This year's conference featured interactive sessions facilitated by experienced CME thought leaders. Topics included updates from the ACCME, grant funding, best practices for needs assessments, evolving technology in education, and much more! This small-scale conference leaves a big impact for those in attendance. MAACME is a great place for us to...

Carcinoid Syndrome: Tackling Educational Gaps

Carcinoid syndrome occurs when carcinoid tumors secrete serotonin or other chemicals into the bloodstream. Because primary symptoms of carcinoid syndrome are associated with other more common diseases, timely recognition is difficult, negatively impacting patients' quality of life and functioning. A CNE-approved Oncology Nursing Strategy Session, Optimizing Management of Carcinoid Syndrome in Patients With Neuroendocrine Tumors , revealed meaningful improvements in nurses' knowledge surrounding ...

Addressing Educational Needs in Castration-Resistant Prostate Cancer

With the substantial expansion of treatment options for castration-resistant prostate cancer (CRPC), including novel hormone therapies, second-generation taxanes, immunotherapy, and bone metastasis-targeted agents, there is a significant need for continuing medical education (CME) to ensure that physicians remain well informed as they seek to optimize treatment for their patients. Assessment data from i3 Health's CME-approved satellite symposium, Castration-Resistant Prostate Cancer: Implementin...

Oncology Nurses Share Their Favorite CNE Formats

i3 Health's surveys of oncology nurses at the Oncology Nursing Society (ONS) 44 th Annual Congress in Anaheim, California, in April 2019 revealed respondents' preferred formats for continuing nursing education (CNE) activities. The surveys focused on educational needs concerning immune checkpoint inhibitors, cyclin-dependent kinase (CDK)4/6 inhibitors, chimeric antigen receptor (CAR) T-cell therapy, poly (ADP)-ribose polymerase (PARP) inhibitors, and biosimilars. Surveys were completed by 304 on...

Copyright © 2019 i3 Health. All rights reserved.